Liang Weizheng, Li Xiushen, Yao Yue, Meng Qingxue, Wu Xueliang, Wang Hao, Xue Jun
Central Laboratory, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Department of General Surgery, The First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Front Pharmacol. 2022 May 23;13:921517. doi: 10.3389/fphar.2022.921517. eCollection 2022.
Patients with colonic adenocarcinoma (COAD) are at relatively high risk of SARS-CoV-2 infection. However, there is a lack of medical strategies to treat COVID-19/COAD comorbidity. Puerarin, a natural product, is a known antiviral, antitumor, and immunomodulatory effect. Therefore, we hypothesised that puerarin could be used to treat COVID-19/COAD patients. Based on network pharmacology and bioinformatics analysis, the potential targets and pharmacological mechanisms of puerarin in COVID-19/COAD were identified. By intersecting therapeutic target genes for puerarin, COVID-19-related genes and COAD-related genes, 42 target genes of puerarin that could potentially treat COVID-19/COAD comorbidity were obtained. By using the 42 potential target genes to construct the protein-protein interaction (PPI) network, we obtained five core target genes, namely RELA, BCL2, JUN, FOS, and MAPK1. The results of bioinformatics analysis revealed that puerarin could be able to treat COVID-19/COAD comorbidity through apoptosis, antiviral, antioxidant, NF-κB signaling pathway, MAPK signaling pathway, IL-17 signaling pathway, TNF signaling pathway, and HIF-1 signaling pathway etc. This study found that puerarin has the potential to treat COVID-19/COAD patients and that the therapeutic target genes obtained in the study may provide clues for the treatment of COVID19/COAD comorbidity.
结肠腺癌（COAD）患者感染新型冠状病毒（SARS-CoV-2）的风险相对较高。然而，目前缺乏治疗新冠病毒病（COVID-19）/COAD合并症的医学策略。葛根素是一种天然产物，具有抗病毒、抗肿瘤和免疫调节作用。因此，我们推测葛根素可用于治疗COVID-19/COAD患者。基于网络药理学和生物信息学分析，确定了葛根素在COVID-19/COAD中的潜在靶点和药理机制。通过将葛根素的治疗靶点基因、COVID-19相关基因和COAD相关基因进行交叉分析，获得了42个可能治疗COVID-19/COAD合并症的葛根素靶点基因。利用这42个潜在靶点基因构建蛋白质-蛋白质相互作用（PPI）网络，得到5个核心靶点基因，即RELA、BCL2、JUN、FOS和MAPK1。生物信息学分析结果表明，葛根素可能通过凋亡、抗病毒、抗氧化、NF-κB信号通路、MAPK信号通路、IL-17信号通路、TNF信号通路和HIF-1信号通路等治疗COVID-19/COAD合并症。本研究发现葛根素具有治疗COVID-19/COAD患者的潜力，且研究中获得的治疗靶点基因可能为治疗COVID-19/COAD合并症提供线索。
